Microvascular thrombosis: experimental and clinical implications
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
A significant amount of clinical and research interest in thrombosis is focused on large vessels (eg, stroke, myocardial infarction, deep venous thrombosis, etc.); however, thrombosis is often present in the microcirculation in a variety of significant human diseases, such as disseminated intravascular coagulation, thrombotic microangiopathy, sickle cell disease, and others. Further, microvascular thrombosis has recently been demonstrated in patients with COVID-19, and has been proposed to mediate the pathogenesis of organ injury in this disease. In many of these conditions, microvascular thrombosis is accompanied by inflammation, an association referred to as thromboinflammation. In this review, we discuss endogenous regulatory mechanisms that prevent thrombosis in the microcirculation, experimental approaches to induce microvascular thrombi, and clinical conditions associated with microvascular thrombosis. A greater understanding of the links between inflammation and thrombosis in the microcirculation is anticipated to provide optimal therapeutic targets for patients with diseases accompanied by microvascular thrombosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545 · cited 1×
“Another autopsy study revealed a more classic appearance of diffuse alveolar damage and hyaline membrane formation without striking microvascular involvement.(333) COVID-19 manifestations further demonstrate the connection between inflammation and thrombosis in the microvasculature.”
BackgroundMIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203 · cited 3×
“The revised Sapporo classification can assist in the clinical diagnosis of APS.”
BackgroundInfluential(2013) · doi:10.1097/01.aog.0000437382.03963.88 · Cited by 3,961
Of Mice and Not Men: Differences between Mouse and Human Immunology
Mestas, J., & Hughes, C. C. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2731 · Cited by 3,822
Circulating mitochondrial DAMPs cause inflammatory responses to injury
Zhang, Q., Raoof, M., Chen, Y., Sumi, Y., Sursal, T., Junger, W., Brohi, K., Itagaki, K., & Hauser, C. J. (2010) · Nature · doi:10.1038/nature08780 · Cited by 3,812 · cited 2×
“One suggested contributory interaction in DIC-trauma is between mitochondrial DNA and TLR9, which also recognizes viral or bacterial DNA.235 Interestingly, mitochondrial DNA shares similar features to pathogen DNA and may contribute to the similar phenotypes of DIC-trauma and DIC-sepsis.236,237 The tissue factor pathw…”
BackgroundFlow-mediated endothelial mechanotransduction
Davies, P. F. (1995) · Physiological Reviews · doi:10.1152/physrev.1995.75.3.519 · Cited by 2,802
Taylor, F., Toh, C.-H., Hoots, K., Wada, H., & Levi, M. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1616068 · Cited by 2,285 · cited 1×
“” Additionally the ISTH developed scoring criteria for DIC comprised of the platelet count, d-dimer (fibrin degradation marker), prothrombin time and fibrinogen level.(202) DIC is associated with both excessive coagulation and enhanced fibrinolysis; the predominance of these pathways can result in a primary phenotype…”
Pathogenesis and Treatment of Sickle Cell Disease
Bunn, H. F. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371107 · Cited by 1,154 · cited 2×
“Sickle cell disease (SCD) is a group of inherited hemolytic anemias arising from mutation in b-globin gene resulting in an abnormal hemoglobin tetramer HbS.(293,294) The most frequent cause of hospitalization in SCD are vaso-occlusive crises (VOCs),(295) which result from a complex interplay of red cells, endothelial…”
BackgroundKeel, M., & Trentz, O. (2005) · Injury · doi:10.1016/j.injury.2004.12.037 · Cited by 885
Pathophysiology of Sickle Cell Disease
Sundd, P., Gladwin, M. T., & Novelli, E. M. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012838 · Cited by 813 · cited 5×
“Sickle cell disease (SCD) is a group of inherited hemolytic anemias arising from mutation in b-globin gene resulting in an abnormal hemoglobin tetramer HbS.(293,294) The most frequent cause of hospitalization in SCD are vaso-occlusive crises (VOCs),(295) which result from a complex interplay of red cells, endothelial…”
BackgroundInfluentialWhy have clinical trials in sepsis failed?
Marshall, J. C. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.01.007 · Cited by 805 · cited 1×
“As in the case of countless other clinical trials that have failed in sepsis, including several other agents targeting coagulation (with promising preclinical data), it is conceivable that additional insight into phenotyping subsets of patients may identify patients to benefit from this and other therapies in a person…”
BackgroundGene therapy in a patient with sickle cell disease
Ribeil, J.-A., Hacein-Bey-Abina, S., Payen, E., Magnani, A., Semeraro, M., Magrin, E., Caccavelli, L., Neven, B., Bourget, P., El Nemer, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609677 · Cited by 696 · cited 1×
“HSCT is currently the only curative option for select group of patients,(324) however, preliminary results are promising for gene therapy.(325) Degos disease.”
BackgroundBelcher, J. D., Chen, C., Nguyen, J., Milbauer, L., Abdulla, F., Alayash, A. I., Smith, A., Nath, K. A., Hebbel, R. P., & Vercellotti, G. M. (2014) · Blood · doi:10.1182/blood-2013-04-495887 · Cited by 695
Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome
PENGO, V., RUFFATTI, A., LEGNANI, C., GRESELE, P., BARCELLONA, D., ERBA, N., TESTA, S., MARONGIU, F., BISON, E., DENAS, G., et al. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03674.x · Cited by 632 · cited 1×
“However, “triple positivity” with positive lupus anticoagulant, anti-cardiolipin and antibeta-2-glycoprotein confers increased risk of developing thrombosis.(269) A “second hit” hypothesis has been proposed where existing antiphospholipid antibodies become pathogenic under inflammatory conditions leading to thrombus f…”
BackgroundPathogenesis of antiphospholipid syndrome: understanding the antibodies
Meroni, P. L., Borghi, M. O., Raschi, E., & Tedesco, F. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.52 · Cited by 620 · cited 1×
“A “second hit” hypothesis has been proposed where existing antiphospholipid antibodies become pathogenic under inflammatory conditions leading to thrombus formation.(270) In vivo models of APS have used either mechanical, chemical or photochemical trauma or LPS to demonstrate increase in thrombosis in APL-infused anim…”
BackgroundKolaczkowska, E., Jenne, C. N., Surewaard, B. G. J., Thanabalasuriar, A., Lee, W.-Y., Sanz, M.-J., Mowen, K., Opdenakker, G., & Kubes, P. (2015) · Nature Communications · doi:10.1038/ncomms7673 · Cited by 584 · cited 1×
“Two examples include defining the role of platelets in bacterial clearance in the liver during blood-borne infection and characterizing formation of neutrophil extracellular traps in vivo during infection.(100,101) Biochemical stimulation.”
BackgroundStroke in a cohort of patients with homozygous sickle cell disease
Balkaran, B., Char, G., Morris, J. S., Thomas, P. W., Serjeant, B. E., & Serjeant, G. R. (1992) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)80897-2 · Cited by 419
Zhang, D., Xu, C., Manwani, D., & Frenette, P. S. (2016) · Blood · doi:10.1182/blood-2015-09-618538 · Cited by 413 · cited 2×
“The activated neutrophils and monocytes can form heterocellular aggregates with platelets and RBCs thus furthering ischemia, vessel occlusion and VOC.(306) In SCD, the composition of large and small vessel thrombosis differs by location.”
BackgroundVillagra, J., Shiva, S., Hunter, L. A., Machado, R. F., Gladwin, M. T., & Kato, G. J. (2007) · Blood · doi:10.1182/blood-2006-12-061697 · Cited by 384 · cited 1×
“Free heme and hemoglobin released from the damaged RBCs can activate platelets, activate neutrophils induce NETs and endothelium dysfunction which promote hypercoagulability.(303) In addition, intravascular hemolysis can directly injure the vessel wall, leading to progressive vessel wall thickness, and anemia from hem…”
BackgroundHemolysis-induced lethality involves inflammasome activation by heme
Dutra, F. F., Alves, L. S., Rodrigues, D., Fernandez, P. L., de Oliveira, R. B., Golenbock, D. T., Zamboni, D. S., & Bozza, M. T. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405023111 · Cited by 353 · cited 1×
“Free heme also promotes NETosis,(312) IL-8 production,(313) and inflammasome activation.(314) The activated neutrophils and monocytes can form heterocellular aggregates with platelets and RBCs thus furthering ischemia, vessel occlusion and VOC.”
BackgroundBarabino, G. A., Platt, M. O., & Kaul, D. K. (2010) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-070909-105339 · Cited by 311 · cited 1×
“Under hypoxia, intraerythrocytic Hb S polymerize to form elongated fibers, which results in changes in cell rigidity, membrane distortion, and hemolysis.(296) Sickling in RBCs is not enough to initiate vaso-occlusion and stasis.”
BackgroundBenefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis
Eloseily, E. M., Weiser, P., Crayne, C. B., Haines, H., Mannion, M. L., Stoll, M. L., Beukelman, T., Atkinson, T. P., & Cron, R. Q. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41103 · Cited by 282 · cited 1×
“Secondary HLH/MAS is treated with a variety of immunosuppressive agents including steroids, cyclosporine and IL-1 cytokine blockade with anakinra.(259,260) Treatment of DIC.”
BackgroundTissue factor as a link between inflammation and coagulation
Witkowski, M., Landmesser, U., & Rauch, U. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.12.001 · Cited by 240 · cited 1×
“The crosstalk between inflammation and thrombosis is extensive and covered by several reviews.(1,207,208) During sepsis, interactions between pathogen-associated patterns (PAMPs) and pattern recognition receptors (PRRs), including toll-like receptors (TLRs), on sentinel immune cells result in increased production of a…”
BackgroundTelen, M. J., Wun, T., McCavit, T. L., De Castro, L. M., Krishnamurti, L., Lanzkron, S., Hsu, L. L., Smith, W. R., Rhee, S., Magnani, J. L., et al. (2015) · Blood · doi:10.1182/blood-2014-06-583351 · Cited by 211
Sickle Red Cell–Endothelium Interactions
KAUL, D. K., FINNEGAN, E., & BARABINO, G. A. (2009) · Microcirculation · doi:10.1080/10739680802279394 · Cited by 208
Embury, S. H. (2004) · Blood · doi:10.1182/blood-2004-02-0713 · Cited by 141 · cited 1×
“Last, in mucosal-intestinal microcirculation, sickle RBCS directly adhere to endothelium resulting in micro-occlusions in postcapillary venules.(307) The difference in contribution of various cellular components may be dependent on local environment such as the presence of high oxygen concentration in lungs.”
BackgroundLung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli
Bennewitz, M. F., Jimenez, M. A., Vats, R., Tutuncuoglu, E., Jonassaint, J., Kato, G. J., Gladwin, M. T., & Sundd, P. (2017) · JCI Insight · doi:10.1172/jci.insight.89761 · Cited by 139
Erythroid DAMPs drive inflammation in SCD
Gladwin, M. T., & Ofori-Acquah, S. F. (2014) · Blood · doi:10.1182/blood-2014-03-563874 · Cited by 113
The Production of Schistocytes by Fibrin Strands (A Scanning Electron Microscope Study)
BULL, B. S., & KUHN, I. N. (1970) · Blood · doi:10.1182/blood.v35.1.104.104 · Cited by 98
Cited by
Pathophysiology of Sickle Cell Disease
Sundd, P., Gladwin, M. T., & Novelli, E. M. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012838 · Cited by 813
Kell, D. B., Laubscher, G. J., & Pretorius, E. (2022) · Biochemical Journal · doi:10.1042/bcj20220016 · Cited by 271
Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad
Ahmed, S., Zimba, O., & Gasparyan, A. Y. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05275-1 · Cited by 251
Tyszko, M., Lemańska-Perek, A., Śmiechowicz, J., Tomaszewska, P., Biecek, P., Gozdzik, W., & Adamik, B. (2023) · Nutrients · doi:10.3390/nu15092100 · Cited by 38
Metadata
- Authors
- Bray, M. A., Sartain, S. E., Gollamudi, J., & Rumbaut, R. E.
- Venue
- Translational Research
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 225
- Pages
- 105-130
- ISSN
- 1878-1810 (ISSN-L)
- 1931-5244
- OpenAlex
- W3027101340
- Cited by
- 115
- References
- 30
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.